<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227457</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0116</org_study_id>
    <nct_id>NCT04227457</nct_id>
  </id_info>
  <brief_title>Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung</brief_title>
  <official_title>Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the overall survival of advanced NSCLC in Latin America.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To describe demographic and socioeconomic characteristics of patients newly diagnosed&#xD;
           with advanced NSCLC&#xD;
&#xD;
        -  To describe diagnostic methods, pathological profile and disease stage at diagnosis of&#xD;
           advanced NSCLC&#xD;
&#xD;
        -  To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC&#xD;
&#xD;
        -  To describe treatment responses, progression and survival times.&#xD;
&#xD;
        -  To describe reasons for treatment discontinuation&#xD;
&#xD;
        -  To identify associations between patient demographics, socioeconomic, pathology,&#xD;
           treatment sequences and overall survival;&#xD;
&#xD;
        -  To define the patient experience of advanced NSCLC and identify unmet needs in their&#xD;
           diagnose and treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival of advanced NSCLC in Latin America</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Time from randomization or initiation of treatment to patient death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the socioeconomical characteristics of the Latin America population with newly advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pathological profile of advanced NSCLC</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Analysis of histology and molecular markers of advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the treatment responses</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the treatment responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Treatment discontinuation</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the reasons for treatment discontinuation</description>
  </secondary_outcome>
  <enrollment type="Actual">700</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The LATINO Lung study will prospectively recruit a minimum of 700 and up to 800 patients&#xD;
        with advanced NSCLC, including locally advanced disease not amenable to curative treatment&#xD;
        or metastatic disease from sites in Argentina, Brazil, Chile, Colombia, and Mexico. Other&#xD;
        countries may be invited to participate.&#xD;
&#xD;
        Patients will be recruited during an initial study period of 3 months, or more to reach the&#xD;
        study minimum sample size, and will be followed for 3 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 years or older;&#xD;
&#xD;
          2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study&#xD;
             (which includes 3 months prior to site activation by LACOG, although they can have&#xD;
             received anti-cancer treatment during that time);&#xD;
&#xD;
          3. Histologically or cytologically confirmed advanced NSCLC:&#xD;
&#xD;
               1. Stage IIIB that progressed after curative therapy (chemoradiation and/or&#xD;
                  surgery);&#xD;
&#xD;
               2. Stage IV metastatic disease (de novo or distant relapse)&#xD;
&#xD;
          4. Any NSCLC histological subtype and molecular mutation;&#xD;
&#xD;
          5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at&#xD;
             diagnosis;&#xD;
&#xD;
          6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted&#xD;
             agents, immunotherapy) or palliative care;&#xD;
&#xD;
          7. Access to patient medical chart for data collection;&#xD;
&#xD;
          8. Willing and able to provide written informed consent and privacy authorization for the&#xD;
             release of personal health information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Oncologico Riojano</name>
      <address>
        <city>La Rioja</city>
        <state>Rioja</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Oncologia De Rosario</name>
      <address>
        <city>Santa Fe</city>
        <state>Rosário</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>Córdoba</city>
        <state>Tucumán</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLION</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOB</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRIO</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sírio- Libanês</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICTr</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Câncer de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Carazinho</name>
      <address>
        <city>Carazinho</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPO</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mãe de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Reichow</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNT Itajaí</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barretos</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COI Américas</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INCA</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AC Camargo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBCC</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Arturo López Pérez</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica del Country</name>
      <address>
        <city>Chapinero</city>
        <state>Bogotá</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncomedica</name>
      <address>
        <city>Montería</city>
        <state>Córdoba</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Robledo</city>
        <state>Medellín</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Nacional Siglo XXI</name>
      <address>
        <city>Ciudad de mexico</city>
        <state>Not Aplicable</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INCan</name>
      <address>
        <city>Ciudad de mexico</city>
        <state>Not Aplicable</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://globocan.iarc.fr/Pages/fact_sheets_population.aspx</url>
    <description>World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012.</description>
  </link>
  <reference>
    <citation>Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013 Apr;14(5):391-436. doi: 10.1016/S1470-2045(13)70048-2.</citation>
    <PMID>23628188</PMID>
  </reference>
  <reference>
    <citation>Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.</citation>
    <PMID>27718847</PMID>
  </reference>
  <reference>
    <citation>Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.</citation>
    <PMID>25470694</PMID>
  </reference>
  <reference>
    <citation>Scagliotti G, Kim T, Crino L, Liu G, Gridelli C. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. Annals of Oncology 27 (Supplement 6): vi552-vi587, 2016 doi:10.1093/annonc/mdw435.41</citation>
  </reference>
  <reference>
    <citation>Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, St Louis J, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldaña K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015 Oct;16(14):1405-38. doi: 10.1016/S1470-2045(15)00218-1. Review.</citation>
    <PMID>26522157</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MCL, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23.</citation>
    <PMID>26105600</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

